Smoking CessationPhase 4NCT02554071
Manitoba Pharmacist Initiated Smoking Cessation Pilot Project
A Phase 4 study testing Pharmacist - Smoking Cessation Support in people with Smoking Cessation, run by University of Manitoba at 1 site in Canada.
Trial summary
A single arm pilot study conducted to assess the feasibility of having Manitoba Pharmacists provide support (product and cognitive) to low-income (receiving social assistance) smokers wishing to quit smoking. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Smoking Cessation
- What is being tested?
- Pharmacist - Smoking Cessation Support
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 119 participants
- Where
- 1 siteCanada
- Study dates
- Jan 2014to Nov 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- smoker
- >= 18 years
- receiving Manitoba Employment and Income Assistance as of January 1st 2015
- Stated desire to quit smoking
- Signed Consent with associated agreement to participate in evaluation and follow-up
Who cannot join
- < 18
- Not on Income Assistance
- Current non-smoker
Trial locations and contacts
1 site in 1 country.
Canada1 site
College of Pharmacy, University of Manitoba
Winnipeg, Manitoba, R6M 1L4
About this study
A single arm pilot study conducted to assess the feasibility of having Manitoba Pharmacists provide support (product and cognitive) to low-income (receiving social assistance) smokers wishing to quit smoking.
Read the detailed description
SYNOPSIS - Manitoba Pharmacist Initiated Smoking Cessation Program Overview Background The Manitoba government supports the role of the pharmacist as an integral part of the primary health care team delivering quality care and service to Manitobans. The role of the Pharmacist is ever evolving and expanding to meet the needs of their clients including comprehensive medication therapy management and expanded preventative expert. Community pharmacists are one of the most accessible health care professionals and provide a wide range of clinical services in the neighborhoods, towns, and cities across this province.
As part of the Manitoba government's wellness initiative, the government is strategically committed towards reducing the use of tobacco through public policy. Smoking is one of the leading causes of death in Manitoba and the use of tobacco is responsible for more than 50% of lung, respiratory, and oral cancers and a substantial factor in cardiovascular disease. While decreases in smoking rates have been achieved in recent years, Manitoba continues to exceed the national average of 17.3%, ranking the province with the third highest smoking prevalence. Manitoba' current smoking rates warrant continued efforts to reduce smoking in youth and adults.
While many believe smoking to be lifestyle choice it is also known to be a changeable lifestyle behavior and a significant determinant of health. It is also known to be a serious addiction that is very difficult to overcome both physically and emotionally. As part of Manitoba's targeted approach to smoking cessation, a partnership has been forged to develop and implement the pilot program: Manitoba Pharmacist Initiated Smoking Cessation Program.
Methodology The role of the pharmacist can best be described as underutilized and often an under recognized resource in smoking cessation programs. For individuals who smoke, many find smoking cessation overwhelming and difficult without assistance, including smoking cessation drugs and ongoing support and counselling. Many pharmacists have received additional knowledge and training specifically for initiating and monitoring a smoking cessation for individual clients. The Manitoba Pharmacist Smoking Cessation Program will provide access for 100 clients to the vital components necessary to quit smoking. Lower socioeconomic status is associated with higher rates of smoking. The Manitoba Employment and Income Assistance program provides support for lower income individuals in Manitoba. This smoking cessation program is a controlled pilot study providing clients with the most appropriate smoking cessation drugs along with the benefit of one to one pharmacist support and counselling.
Smoking Cessation Program Objectives
The following are the program objectives:
- Establish a provincial pilot smoking cessation program
- Reduce the number of Manitobans who smoke
- Enhance utilization of the pharmacist in preventative health care delivery
Program Scope A. Target Population
- 100 Manitoba residents over the age of 18 who are Manitoba Employment and Income Assistance active program participants as of January 01, 2014
- Provide written consent to participate in a smoking cessation program
- Agree to participate in the counselling sessions and smoking cessation behavior readiness
- Agree to participate in an evaluative process and follow up study
- Participation Provider (Pharmacy and pharmacist)
- Pharmacy/Pharmacists - Up to fifteen pharmacies throughout Manitoba who employ pharmacists professionally trained in QUIT and/or Catalyst, have previous experience providing smoking cessation services to patients, who are willing and able to commit to pilot project timelines, and who receive pharmacy manager approval will be eligible to apply to participate in this program.
- In December 2013, MPhA will distribute application forms to each pharmacy for their voluntary consideration for participation and response to the call for applications. Each application form consists of a letter of introduction to explain the program and application process, a pharmacist manager application form, and pharmacist application form(s). The MPhA is the provincial regulatory body for pharmacists and pharmacies in Manitoba and thus has access to all pharmacy contact information. MPhA has agreed to utilize their mailing list and distribution system to communicate with all pharmacies in the province to ensure that equal access to any pharmacy and pharmacist in the province is achieved.
- The Steering Committee will establish a Pharmacy Selection Sub-Committee to confidentially review all application forms for completeness and to select suitable complete a random selection process of all complete and eligible applications.
- Up to 15 pharmacies in Manitoba who meet the provider eligibility criteria will be selected by the Pharmacy Selection Sub-Committee. All applicants will receive an outcome letter from the Program Manager following the selection process.
- Successful pharmacy applicants will receive an orientation training program in the first week of January 2014 to share and educate pilot project details, participant recruitment processes, program implementation processes, methodology to complete participant informed consent and program surveys, evaluation requirements, and professional pharmacy reimbursement processes, and participant product reimbursement options.
Client Participation
- Eligible participants in the pilot project include and Manitoba adult who meets the criteria of the targeted population cohort, and who have identified as being ready to quit smoking, will be eligible for the program.
- Pharmacists participating as providers in the smoking cessation pilot project will be responsible for identifying eligible adults within their patient population as eligible for program participation.
- All pharmacists in Manitoba are PHIA compliant.
- Pharmacist providers will share with each potential participant a program information sheet, informed consent form, and access to a pharmacy staff person (pharmacy assistant/technician) not related to the pilot project and Pilot Project Project Manager contact information for access to pilot project information and independent decision making for project participation.
- Completion of the Informed Consent Form will be independently completed by the potential applicant.
- Support from an assigned pharmacy staff member not related to the pilot project will be made available should the potential applicant request.
- Potential applicants will be encouraged to consult with their primary health care provider.
- Each project participant:
- Be introduced to the smoking cessation program and if interested given the informed consent to review. They may also be provided with some general educational materials on smoking cessation ii. Once the participant has had sufficient time to review the consent and has had all questions answered, the pharmacy assistant/technician will obtain informed consent. iii. After consent has been obtained the patient will be provided with some forms to complete to assess their current smoking patterns and readiness to quit. When the completed forms are returned an initial assessment interview will be booked with the pharmacist. iv. During the initial assessment interview:
- The pharmacist will assess the level of dependence from the completed Fagerstrom Tolerance Scale and assess the motivations for smoking from the Why Test.
- Potential drug interactions between medications and smoking/smoking cessation will be assessed.
- The participant will be introduced to the Smoking Cessation Form and asked to record the symptoms, triggers, cessation product use and side effects on a daily basis.
- The participant will be provided with a variety of educational materials to help guide their individualized quit plan (How Do I Want to Quit?, Why Do I Want to Quit?, When Do I Want To Quit?)
- The pharmacist will work with the participant to complete the Pre-Quit Planning form
- Additional Educational materials may be provided as needed ( Count Down to Quit Date, Breaking the Cycle of Addiction Date, My Reasons to Quit Smoking, Enlisting Support) v. Quit Day Visit:
- The pharmacist will work with the participant to complete the Quit Day Plan. 2. The participant will be provided with the Quit Diary to record smoking 3. Additional Educational materials will be provided as needed (Managing Withdrawal Symptoms, Minimizing Weight Gain, Dealing with the Urge to Smoke, Managing Slips and Relapse, List of Resources).
- Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups. vi. Phone Follow-up - 1 Week Post Quit
- The pharmacist will provide telephone follow-up and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient. vii. 1 Month Post Quit Visit
- The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient. viii. 3 Month Quit Visit
- The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient.
- Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups. ix. Phone Follow-up - 6 Month Post Quit
- The pharmacist will provide telephone follow-up and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient.
- Make a transition plan to ensure the participant has access to remaining to necessary support and suitable covered medications to maintain smoking cessation.
- Program Duration Total duration of the study will be a 6-15 months. The participant will have access to smoking cessation pharmacy counseling services and smoking cessation products for a period of three months from the initiation in the pilot project. The intervention component of the pilot project will be available between January and April 2015.
- Conditions
- Smoking Cessation
- Being tested
- Pharmacist - Smoking Cessation Support
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacist - Smoking Cessation SupportOther
Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
| Study group | Role | What they receive |
|---|---|---|
| Pharmacist - Smoking Cessation Support' | Experimental | Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling Receives: Other: Pharmacist - Smoking Cessation Support |
What is being measured
The primary outcome is the main question the study is designed to answer.
Smoking Cessation Assessment
Self-reported Smoking Cessation on Standardized Form
Measured: 6 months
Secondary outcomes (4)
Smoking Cessation Assessment
Self-reported Smoking Cessation on Standardized Form
Measured: 1 month
Smoking Cessation Assessment
Self-reported Smoking Cessation on Standardized Form
Measured: 3 months
Smoking Cessation Product
Smoking Cessation Product Used and Cost
Measured: 3 months
Quit Diary
Record of Continued Smoking and Symptoms
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2015 (estimated)
- Study startJan 2014
- Primary completionNov 2014
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- More trials run by University of ManitobaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 119 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Collaborators
- Govenment of Manitoba, Canadian Foundation for Pharmacy, Neighbourhood Pharmacy Association of Canada
- Responsible party
- Principal investigator, Dr. Shawn Bugden, University of Manitoba
- Investigators
- Shawn C Bugden, PharmD, Principal investigator, College of Pharmacy, University of Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02554071
- Sponsor's protocol ID
- H2013:459
- Status last verified
- Sep 2015
- First submitted
- 16 Sep 2015
- Last updated
- 18 Sep 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Manitoba Pharmacist Initiated Smoking Cessation Pilot Project
- ClinicalTrials.gov ID
- NCT02554071
- Acronym / sponsor ID
- H2013:459
- Conditions
- Smoking Cessation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Collaborators
- Govenment of Manitoba, Canadian Foundation for Pharmacy, Neighbourhood Pharmacy Association of Canada
- Study start
- Jan 2014
- Primary completion
- Nov 2014 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 18 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A single arm pilot study conducted to assess the feasibility of having Manitoba Pharmacists provide support (product and cognitive) to low-income (receiving social assistance) smokers wishing to quit smoking.
Detailed description
SYNOPSIS - Manitoba Pharmacist Initiated Smoking Cessation Program Overview Background The Manitoba government supports the role of the pharmacist as an integral part of the primary health care team delivering quality care and service to Manitobans. The role of the Pharmacist is ever evolving and expanding to meet the needs of their clients including comprehensive medication therapy management and expanded preventative expert. Community pharmacists are one of the most accessible health care professionals and provide a wide range of clinical services in the neighborhoods, towns, and cities across this province.
As part of the Manitoba government's wellness initiative, the government is strategically committed towards reducing the use of tobacco through public policy. Smoking is one of the leading causes of death in Manitoba and the use of tobacco is responsible for more than 50% of lung, respiratory, and oral cancers and a substantial factor in cardiovascular disease. While decreases in smoking rates have been achieved in recent years, Manitoba continues to exceed the national average of 17.3%, ranking the province with the third highest smoking prevalence. Manitoba' current smoking rates warrant continued efforts to reduce smoking in youth and adults.
While many believe smoking to be lifestyle choice it is also known to be a changeable lifestyle behavior and a significant determinant of health. It is also known to be a serious addiction that is very difficult to overcome both physically and emotionally. As part of Manitoba's targeted approach to smoking cessation, a partnership has been forged to develop and implement the pilot program: Manitoba Pharmacist Initiated Smoking Cessation Program.
Methodology The role of the pharmacist can best be described as underutilized and often an under recognized resource in smoking cessation programs. For individuals who smoke, many find smoking cessation overwhelming and difficult without assistance, including smoking cessation drugs and ongoing support and counselling. Many pharmacists have received additional knowledge and training specifically for initiating and monitoring a smoking cessation for individual clients. The Manitoba Pharmacist Smoking Cessation Program will provide access for 100 clients to the vital components necessary to quit smoking. Lower socioeconomic status is associated with higher rates of smoking. The Manitoba Employment and Income Assistance program provides support for lower income individuals in Manitoba. This smoking cessation program is a controlled pilot study providing clients with the most appropriate smoking cessation drugs along with the benefit of one to one pharmacist support and counselling.
Smoking Cessation Program Objectives
The following are the program objectives:
- Establish a provincial pilot smoking cessation program
- Reduce the number of Manitobans who smoke
- Enhance utilization of the pharmacist in preventative health care delivery
Program Scope A. Target Population
- 100 Manitoba residents over the age of 18 who are Manitoba Employment and Income Assistance active program participants as of January 01, 2014
- Provide written consent to participate in a smoking cessation program
- Agree to participate in the counselling sessions and smoking cessation behavior readiness
- Agree to participate in an evaluative process and follow up study
- Participation Provider (Pharmacy and pharmacist)
- Pharmacy/Pharmacists - Up to fifteen pharmacies throughout Manitoba who employ pharmacists professionally trained in QUIT and/or Catalyst, have previous experience providing smoking cessation services to patients, who are willing and able to commit to pilot project timelines, and who receive pharmacy manager approval will be eligible to apply to participate in this program.
- In December 2013, MPhA will distribute application forms to each pharmacy for their voluntary consideration for participation and response to the call for applications. Each application form consists of a letter of introduction to explain the program and application process, a pharmacist manager application form, and pharmacist application form(s). The MPhA is the provincial regulatory body for pharmacists and pharmacies in Manitoba and thus has access to all pharmacy contact information. MPhA has agreed to utilize their mailing list and distribution system to communicate with all pharmacies in the province to ensure that equal access to any pharmacy and pharmacist in the province is achieved.
- The Steering Committee will establish a Pharmacy Selection Sub-Committee to confidentially review all application forms for completeness and to select suitable complete a random selection process of all complete and eligible applications.
- Up to 15 pharmacies in Manitoba who meet the provider eligibility criteria will be selected by the Pharmacy Selection Sub-Committee. All applicants will receive an outcome letter from the Program Manager following the selection process.
- Successful pharmacy applicants will receive an orientation training program in the first week of January 2014 to share and educate pilot project details, participant recruitment processes, program implementation processes, methodology to complete participant informed consent and program surveys, evaluation requirements, and professional pharmacy reimbursement processes, and participant product reimbursement options.
Client Participation
- Eligible participants in the pilot project include and Manitoba adult who meets the criteria of the targeted population cohort, and who have identified as being ready to quit smoking, will be eligible for the program.
- Pharmacists participating as providers in the smoking cessation pilot project will be responsible for identifying eligible adults within their patient population as eligible for program participation.
- All pharmacists in Manitoba are PHIA compliant.
- Pharmacist providers will share with each potential participant a program information sheet, informed consent form, and access to a pharmacy staff person (pharmacy assistant/technician) not related to the pilot project and Pilot Project Project Manager contact information for access to pilot project information and independent decision making for project participation.
- Completion of the Informed Consent Form will be independently completed by the potential applicant.
- Support from an assigned pharmacy staff member not related to the pilot project will be made available should the potential applicant request.
- Potential applicants will be encouraged to consult with their primary health care provider.
- Each project participant:
- Be introduced to the smoking cessation program and if interested given the informed consent to review. They may also be provided with some general educational materials on smoking cessation ii. Once the participant has had sufficient time to review the consent and has had all questions answered, the pharmacy assistant/technician will obtain informed consent. iii. After consent has been obtained the patient will be provided with some forms to complete to assess their current smoking patterns and readiness to quit. When the completed forms are returned an initial assessment interview will be booked with the pharmacist. iv. During the initial assessment interview:
- The pharmacist will assess the level of dependence from the completed Fagerstrom Tolerance Scale and assess the motivations for smoking from the Why Test.
- Potential drug interactions between medications and smoking/smoking cessation will be assessed.
- The participant will be introduced to the Smoking Cessation Form and asked to record the symptoms, triggers, cessation product use and side effects on a daily basis.
- The participant will be provided with a variety of educational materials to help guide their individualized quit plan (How Do I Want to Quit?, Why Do I Want to Quit?, When Do I Want To Quit?)
- The pharmacist will work with the participant to complete the Pre-Quit Planning form
- Additional Educational materials may be provided as needed ( Count Down to Quit Date, Breaking the Cycle of Addiction Date, My Reasons to Quit Smoking, Enlisting Support) v. Quit Day Visit:
- The pharmacist will work with the participant to complete the Quit Day Plan. 2. The participant will be provided with the Quit Diary to record smoking 3. Additional Educational materials will be provided as needed (Managing Withdrawal Symptoms, Minimizing Weight Gain, Dealing with the Urge to Smoke, Managing Slips and Relapse, List of Resources).
- Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups. vi. Phone Follow-up - 1 Week Post Quit
- The pharmacist will provide telephone follow-up and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient. vii. 1 Month Post Quit Visit
- The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient. viii. 3 Month Quit Visit
- The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient.
- Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups. ix. Phone Follow-up - 6 Month Post Quit
- The pharmacist will provide telephone follow-up and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
- They will complete the Smoking Cessation Assessment Form with the patient.
- Make a transition plan to ensure the participant has access to remaining to necessary support and suitable covered medications to maintain smoking cessation.
- Program Duration Total duration of the study will be a 6-15 months. The participant will have access to smoking cessation pharmacy counseling services and smoking cessation products for a period of three months from the initiation in the pilot project. The intervention component of the pilot project will be available between January and April 2015.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pharmacist - Smoking Cessation Support' | Experimental | Other: Pharmacist - Smoking Cessation SupportActive Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- smoker
- >= 18 years
- receiving Manitoba Employment and Income Assistance as of January 1st 2015
- Stated desire to quit smoking
- Signed Consent with associated agreement to participate in evaluation and follow-up
Key exclusion criteria (3 listed)
- < 18
- Not on Income Assistance
- Current non-smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmacist - Smoking Cessation SupportIntervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling | Other | Pharmacist - Smoking Cessation Support' |
Primary outcome
Smoking Cessation Assessment
Time frame: 6 months
Self-reported Smoking Cessation on Standardized Form
4 secondary outcomes
Smoking Cessation Assessment
Time frame: 1 month
Smoking Cessation Assessment
Time frame: 3 months
Smoking Cessation Product
Time frame: 3 months
Quit Diary
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2015.
Related trials for Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Not yet recruiting
Smoking Cessation Program for Lao People With HIV
Smoking Cessation, HIV
RecruitingPhase 3
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shawn C Bugden, PharmD principal investigator
College of Pharmacy, University of Manitoba
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Pharmacist - Smoking Cessation Support in people with Smoking Cessation, run by University of Manitoba at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Smoking Cessation Assessment (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2015.